Given the recent approval and addition of the PSMA PET/CT scan to the PC clinical care pathway, the progression to PSMA PET/CT-derived radiomics in risk stratification and personalized management of PC is a logical and potentially transformative advancement. The gene discussed is FOLH1; the disease is pachyonychia congenita.